Nara Medical University Hospital

Nara, Kashihara 634-8522

3 studies enrolling now · 12 studies all time

What they study most

Alzheimer Disease, Borderline Personality Disorder, Depressive Disorder, Major, Heart Failure, Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Non-alcoholic Steatohepatitis (NASH), Schizophrenia

Studies at this site

• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study — Stopped early
• Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) — Completed
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months — Stopped early
• A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression — Completed
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) — Completed
• A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder — Completed
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia — Completed
• BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. — Completed